Symbol="AGLE"
AssetType="Common Stock"
Name="Aeglea Bio Therapeutics Inc"
Description="Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapies for the treatment of patients and families with rare metabolic diseases. The company is headquartered in Austin, Texas."
CIK="1636282"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="901 S. MOPAC EXPRESSWAY, STE. 250, BARTON OAKS PLAZA ONE, AUSTIN, TX, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="47037400"
EBITDA="-77598000"
PERatio="None"
PEGRatio="0"
BookValue="0.515"
DividendPerShare="0"
DividendYield="0"
EPS="-0.73"
RevenuePerShareTTM="0.013"
ProfitMargin="0"
OperatingMarginTTM="-67.94"
ReturnOnAssetsTTM="-0.73"
ReturnOnEquityTTM="-1.633"
RevenueTTM="1165000"
GrossProfitTTM="-262000"
DilutedEPSTTM="-0.73"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.855"
AnalystTargetPrice="1.68"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.084"
PriceToBookRatio="0.351"
EVToRevenue="1.265"
EVToEBITDA="0.535"
Beta="2.551"
num_52WeekHigh="1.56"
num_52WeekLow="0.106"
num_50DayMovingAverage="0.282"
num_200DayMovingAverage="0.457"
SharesOutstanding="78409000"
DividendDate="None"
ExDividendDate="None"
symbol="AGLE"
open="0.58"
high="0.62"
low="0.58"
price="0.59"
volume="642717.00"
latest_trading_day="2023-07-21"
previous_close="0.60"
change="-0.01"
change_percent="-0.9683%"
aroon_positive_momentum_days="21"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="High Volatility / Hold Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="21"
Volume_recent_avg="4398060"
Change_recent_avg="0.01"
Delta_recent_avg="0.04"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="-2.44"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="21"
Aroon_momentum_negative="79"
image_negative_thumbnail_id_1="153"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0023.jpeg"
image_negative_thumbnail_id_2="512"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0093.jpeg"
image_neutral_thumbnail_id_1="569"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0030.jpeg"
image_neutral_thumbnail_id_2="598"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0001.jpeg"
image_positive_thumbnail_id_1="998"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0160.jpeg"
image_positive_thumbnail_id_2="977"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0139.jpeg"
image_professor_thumbnail_id_1="1180"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
image_professor_thumbnail_id_2="1196"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
